Biggest, Most Diverse Fleet in Olympic Sailing Gets Ready to Hit the Water

Matt Wearn, of Australia, poses for a portrait before men's dinghy practice at the 2024 Summer Olympics, Thursday, July 25, 2024, in Marseille, France (AP Photo/Jacquelyn Martin)
Matt Wearn, of Australia, poses for a portrait before men's dinghy practice at the 2024 Summer Olympics, Thursday, July 25, 2024, in Marseille, France (AP Photo/Jacquelyn Martin)
TT

Biggest, Most Diverse Fleet in Olympic Sailing Gets Ready to Hit the Water

Matt Wearn, of Australia, poses for a portrait before men's dinghy practice at the 2024 Summer Olympics, Thursday, July 25, 2024, in Marseille, France (AP Photo/Jacquelyn Martin)
Matt Wearn, of Australia, poses for a portrait before men's dinghy practice at the 2024 Summer Olympics, Thursday, July 25, 2024, in Marseille, France (AP Photo/Jacquelyn Martin)

The biggest and most diverse fleet of the 2024 Olympics' sailing events, the one-person dinghy, is scheduled to hit the water Thursday in sweltering Marseille.

The small, white-sailed boats — formerly known as lasers, now called ILCA 6 for women and ILCA 7 for men — go slower, sail deeper into the water and have a less spectacular design than many other vessels in the Olympic marina.

But to the sailors who race them, they are the purest form of the sport, The AP reported.

“It’s very pure and it’s very close — you’ve got to work for every inch,” said Matt Wearn, 28, of Australia. “You’re not looking to win by a mile, you’re looking to win by a meter.”

Wearn is seeking to defend the gold he won in the event in the Tokyo Games — and so is Anne-Marie Rindom of Denmark, 33, who in addition to a gold from Tokyo has a bronze from Rio de Janeiro and first competed in the London Games in 2012.

“It’s all about the sailor in the boat,” said Rindom, whose parents first took her sailing when she was 2 weeks old. She competed in her first regatta at age 9.

In this class, boats are provided to Olympians only about a week before the Games, leveling the playing field. That makes consistently nailing the smallest tactical detail — an inch of advantage at the starting line, catching a sudden wave to surf ahead, balancing for the additional weight of branding stickers on the sail — the key to medal.

“All these little accuracies make a huge difference,” said Micky Beckett, 29, of Britain. “Being on top of your mental game is absolutely everything.”

That’s also because the boats are so versatile and “basically unsinkable,” in Beckett’s words, that they can — and do — sail in any kind of weather, for hourlong regattas.

Not that physical strength is negligible. In big swells, with spray coming straight at the athletes’ bodies, races can be “quite battering, like being thrown into a washing machine and spat out the other side,” Wearn said. So far in Marseille, the challenge has been the opposite: very low winds under a scorching sun, which can also be draining.

The boats are relatively inexpensive to buy and transport, designed to fit the top of a car. So they’re the star of World Sailing’s development program, which aims to support athletes from nations without long histories in Olympic sailing, from El Salvador to Fiji to Mozambique.

“It’s cool to see it’s not always the same five nations,” said Nethra Kumanan, 26, of India, who qualified for the Games in the ILCA 6 at the so-called last-chance regatta under the program. “We hope we can give them a fight.”

And a fight it is, because the event features almost twice as many boats as the other sailing categories — more than 80.

“It’s the hardest to win, it’s very equal,” said Tom Saunders, 32, of New Zealand, whose brother also was an Olympic sailor but in the two-person boats.

“It feels like it’s not over till the very end,” echoed Maud Jayet, 28, of Switzerland, who learned sailing on Alpine lakes and competed in the Tokyo Games.

Like her and most sailors in this category, Marit Bouwmeester, 36, of the Netherlands, enjoys shouldering all the responsibility alone for racing strategy, unlike in two-person boats.

Her tactics have been paying off — she’s medaled in the last three Olympics, snagging silver in London, gold in Rio and bronze in Tokyo. In Marseille, however, she’s trying something new — competing as the mother of a 2-year-old daughter.

“It’s a challenge to do motherhood and top sports,” Bouwmeester said, especially to find the time to train hard and then recover, but there’s also a mental advantage. “If I have a bad day, I can go back to being a mother.”

Pavlos Kontides, 34 and the first athlete from Cyprus to win a medal — for the then-laser in 2012 — is coming back for his fifth Olympics, also with a toddler in tow who changed his perspective about the relative importance of medals. Not that he doesn’t want one.

“The fire is burning,” he said. “When you’re on a boat, you’re in a different world. You have your own reality on the sea.”

Independence, simplicity, accessibility — for many athletes, that’s what Olympic dinghies represent.

Having started sailing by his village in West Wales when he was 5, Beckett says he’s still grateful for his parents’ sacrifices driving all around the UK and camping out to bring him to regattas. He hopes the Olympic spotlight can interest more children in taking up this streamlined version of the sport.

“(Sailing) is not as confusing or expensive as it looks,” he said. “You don’t have to be genetically anything — sailing has a home for anybody.”



Weight Loss Drug Cut Heart Failure Risk by 38% in Trial

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
TT

Weight Loss Drug Cut Heart Failure Risk by 38% in Trial

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights

Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits.

The drug, also known as tirzepatide, reduced the risk of a composite of heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death by 38% compared to a placebo, according to Reuters.

The trial enrolled 731 patients across 10 countries who have heart failure with preserved ejection fraction and obesity.

The condition "accounts for nearly half of all heart failure cases, and in the US almost 60% of those impacted also live with obesity," Jeff Emmick, Lilly senior vice president, product development, said in a statement.

Lilly said the study also showed the drug significantly improved heart failure symptoms and physical limitations.

Heart failure is a condition in which the heart is unable to pump enough blood to meet the body's needs. It is associated with a high burden of symptoms and physical limitations affecting daily life, including fatigue, shortness of breath, reduced ability to exercise and swelling of extremities.

Trial patients on tirzepatide were given weekly injections of the highest dose they could tolerate, up to 15 milligrams, and were followed for a median of two years.

The drug led to 15.7% weight loss in the combined population of people with and without type 2 diabetes, compared with 2.2% for the placebo, Lilly said. For the non-diabetes patients, weight loss was 13.9%.

Zepbound, also sold under the brand name Mounjaro for type 2 diabetes, is part of a top-selling class of drugs designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow digestion and decrease appetite.

Lilly said the most common side effects for trial patients on tirzepatide were diarrhea, nausea, constipation and vomiting.

The company said it plans to submit the heart failure results to the US Food and Drug Administration and other regulatory agencies starting later this year. The findings will also be presented at an upcoming medical meeting and submitted to a peer-reviewed journal.

Novo Nordisk has reported data showing its GLP-1 weight loss drug Wegovy reduces heart failure symptoms.